

# Kento Imajo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3320563/kento-imajo-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114  
papers

3,014  
citations

28  
h-index

52  
g-index

134  
ext. papers

4,117  
ext. citations

5  
avg, IF

4.85  
L-index

#	Paper	IF	Citations
114	Two-step strategy, FIB-4 followed by magnetic resonance elastography, for detecting advanced fibrosis in NAFLD.. <i>Clinical Gastroenterology and Hepatology</i> , <b>2022</b> ,	6.9	1
113	Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. <i>Metabolism: Clinical and Experimental</i> , <b>2022</b> , 126, 154911	12.7	2
112	Gastroesophageal varices evaluation using spleen-dedicated stiffness measurement by vibration-controlled transient elastography.. <i>JGH Open</i> , <b>2022</b> , 6, 11-19	1.8	1
111	Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.. <i>Hepatology</i> , <b>2021</b> ,	11.2	3
110	Utility of Ultrasound-Guided Attenuation Parameter for Grading Steatosis With Reference to MRI-PDFF in a Large Cohort. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	2
109	Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. <i>Journal of Gastroenterology</i> , <b>2021</b> , 56, 1022-1032	6.9	6
108	Endotoxins and Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 770986	5.7	9
107	MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Gut</i> , <b>2021</b> , 70, 1946-1953	19.2	18
106	Vitamin B6 efficacy in the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, single-center trial. <i>Journal of Clinical Biochemistry and Nutrition</i> , <b>2021</b> , 68, 181-186	3.1	4
105	Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 2275-2284	4.8	6
104	Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort. <i>PLoS ONE</i> , <b>2021</b> , 16, e0249491	3.7	2
103	Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. <i>Hepatology Communications</i> , <b>2021</b> ,	6	9
102	MRI-Based Quantitative R2 Mapping at 3 Tesla Reflects Hepatic Iron Overload and Pathogenesis in Nonalcoholic Fatty Liver Disease Patients. <i>Journal of Magnetic Resonance Imaging</i> , <b>2021</b> ,	5.6	1
101	The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
100	Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. <i>Hepatology Communications</i> , <b>2021</b> , 5, 559-572	6	7
99	Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 609-623	5.6	8
98	Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. <i>BMJ Open Diabetes Research and Care</i> , <b>2021</b> , 9,	4.5	14

97	FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. <i>Life</i> , <b>2021</b> , 11,	3	6
96	Diagnostic Accuracy of Two-Dimensional Shear Wave Elastography[For Liver Fibrosis: A Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	2
95	MRE plus FIB-4 (MEFIB) versus FAST in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Hepatology</i> , <b>2021</b> ,	11.2	6
94	Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor [modulator (SPPARM)] versus placebo in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 1263-1277	6.1	14
93	Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease. <i>Internal Medicine</i> , <b>2021</b> , 60, 3391-3399	1.1	1
92	Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: A multicenter study. <i>Hepatology Research</i> , <b>2020</b> , 50, 955-965	5.1	6
91	Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	20
90	Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study. <i>Trials</i> , <b>2020</b> , 21, 453	2.8	2
89	Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	22
88	Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , <b>2020</b> , 50, 682-692	5.1	22
87	Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study. <i>JGH Open</i> , <b>2020</b> , 4, 497-502	1.8	12
86	Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver. <i>Diagnostics</i> , <b>2020</b> , 10,	3.8	9
85	Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). <i>Contemporary Clinical Trials Communications</i> , <b>2020</b> , 17, 100516	1.8	7
84	A review of conventional and newer generation microwave ablation systems for hepatocellular carcinoma. <i>Journal of Medical Ultrasonics (2001)</i> , <b>2020</b> , 47, 265-277	1.4	11
83	Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 88	3	12
82	Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes. <i>Hepatology Research</i> , <b>2020</b> , 50, 831-839	5.1	21
81	VI. Screening High-risk Non-alcoholic Fatty Liver Disease (NAFLD). <i>The Journal of the Japanese Society of Internal Medicine</i> , <b>2020</b> , 109, 47-55	0	
80	A case of hepatitis B virus reactivation with hemochromatosis after allogeneic bone marrow transplantation for acute myeloid leukemia. <i>Acta Hepatologica Japonica</i> , <b>2020</b> , 61, 504-512	0.3	

79	Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. <i>Journal of Gastroenterology</i> , <b>2020</b> , 55, 428-440	6.9	29
78	Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 996-1007	18.8	7
77	Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs. <i>Diagnostics</i> , <b>2020</b> , 10,	3.8	3
76	Advances in ultrasound elastography for nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , <b>2020</b> , 47, 521-533	1.4	8
75	Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Diagnostics</i> , <b>2020</b> , 10,	3.8	8
74	Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , <b>2020</b> , 47, 535-548	1.4	6
73	Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease. <i>BMJ Open</i> , <b>2020</b> , 10, e037961	3	3
72	Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	11
71	Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1626-1632	4	12
70	Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , <b>2019</b> , 49, 1136-1146	5.1	11
69	Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , <b>2019</b> , 49, 872-880	5.1	10
68	Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 630-637.e8	6.9	135
67	Infection phase is a predictor of pruritus in patients with hepatitis B virus infection. <i>Biomedical Reports</i> , <b>2019</b> , 11, 63-69	1.8	0
66	Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2570-2580.e37	6.9	40
65	Microbiota in Non-alcoholic Liver Disease <b>2019</b> , 103-111		
64	FRI-312-Increased levels of bile acid in feces plays an important role in pathophysiology of non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e534	13.4	2
63	Three-dimensional analysis of pancreatic fat by fat-water magnetic resonance imaging provides detailed characterization of pancreatic steatosis with improved reproducibility. <i>PLoS ONE</i> , <b>2019</b> , 14, e0224921	3.7	12
62	HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1390-1395	4	38

61	Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 69-82	4	15
60	Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1411-1416	4	4
59	Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. <i>Contemporary Clinical Trials</i> , <b>2018</b> , 69, 40-47	2.3	3
58	Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 1795-1803	4	27
57	Angiotensin II Type 1 Receptor-associated Protein Inhibits Angiotensin II-induced Insulin Resistance with Suppression of Oxidative Stress in Skeletal Muscle Tissue. <i>Scientific Reports</i> , <b>2018</b> , 8, 2846	4.9	11
56	Identification of the genomic region under epigenetic regulation during non-alcoholic fatty liver disease progression. <i>Hepatology Research</i> , <b>2018</b> , 48, E320-E334	5.1	23
55	Prevalence of pruritus in patients with chronic liver disease: A multicenter study. <i>Hepatology Research</i> , <b>2018</b> , 48, E252-E262	5.1	27
54	Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin. <i>Scientific Reports</i> , <b>2018</b> , 8, 11365	4.9	46
53	A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. <i>Scientific Reports</i> , <b>2018</b> , 8, 10434	4.9	25
52	The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. <i>Journal of Gastroenterology</i> , <b>2018</b> , 53, 1216-1224	6.9	37
51	New microwave ablation system for unresectable liver tumors that forms large, spherical ablation zones. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 2007-2014	4	9
50	Magnetic resonance elastography increases usefulness and safety of non-invasive screening for esophageal varices. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 2022-2028	4	15
49	Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. <i>Journal of Gastroenterology</i> , <b>2018</b> , 53, 181-196	6.9	46
48	Identification of differentially methylated region (DMR) networks associated with progression of nonalcoholic fatty liver disease. <i>Scientific Reports</i> , <b>2018</b> , 8, 13567	4.9	21
47	Non-Invasive Diagnosis of Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1409-1411	0.7	12
46	Identification of core gene networks and hub genes associated with progression of non-alcoholic fatty liver disease by RNA sequencing. <i>Hepatology Research</i> , <b>2017</b> , 47, 1445-1458	5.1	10
45	Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. <i>Scientific Reports</i> , <b>2017</b> , 7, 42477	4.9	58
44	Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. <i>BMC Gastroenterology</i> , <b>2017</b> , 17, 96	3	40

43	Characteristics of Fecal Microbiota in Japanese Patients with Nonalcoholic Fatty Liver Disease: A Connection among Gut-Permeability, Endotoxin and NAFLD. <i>Gastroenterology</i> , <b>2017</b> , 152, S1200	13.3	5
42	Reply. <i>Gastroenterology</i> , <b>2016</b> , 151, 375-6	13.3	
41	Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis. <i>Scientific Reports</i> , <b>2016</b> , 6, 22251	4.9	48
40	Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. <i>Journal of Gastroenterology</i> , <b>2016</b> , 51, 586-96	6.9	33
39	Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. <i>Gastroenterology</i> , <b>2016</b> , 150, 626-637.e7	13.3	438
38	The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. <i>PLoS ONE</i> , <b>2016</b> , 11, e0146337	3.7	105
37	Characteristics of non-obese non-alcoholic fatty liver disease: Effect of genetic and environmental factors. <i>Hepatology Research</i> , <b>2016</b> , 46, 1011-8	5.1	39
36	Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. <i>Cancer</i> , <b>2016</b> , 122, 2041-9	6.4	109
35	Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 494-502	13.4	53
34	Screening of nonalcoholic fatty liver disease in patients with coronary heart disease by transient elastography: proceed with caution. <i>Wiener Klinische Wochenschrift</i> , <b>2015</b> , 127, 75-6	2.3	
33	Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model. <i>BMC Gastroenterology</i> , <b>2015</b> , 15, 42	3	20
32	Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution. <i>BMC Gastroenterology</i> , <b>2015</b> , 15, 177	3	23
31	Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1009-14	4	40
30	Are platelets count useful for detecting the grade of steatosis?. <i>Hepatitis Monthly</i> , <b>2015</b> , 15, e28957	1.8	2
29	The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , <b>2014</b> , 49, 1163-74	6.9	4
28	Uric acid levels decrease with fibrosis progression in patients with nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , <b>2014</b> , 47, 1138-9	3.5	7
27	LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study. <i>PLoS ONE</i> , <b>2014</b> , 9, e115403	3.7	25
26	Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: Proceed with caution. <i>Hepatology Research</i> , <b>2014</b> , 44, E499-502	5.1	17

25	Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis. <i>Journal of Gastroenterology</i> , <b>2014</b> , 49, 295-304	6.9	6
24	Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. <i>Journal of Gastroenterology</i> , <b>2014</b> , 49, 1477-84	6.9	87
23	Microbiota and nonalcoholic steatohepatitis. <i>Seminars in Immunopathology</i> , <b>2014</b> , 36, 115-32	12	29
22	Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 10108-14	5.6	16
21	Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. <i>Journal of Gastroenterology</i> , <b>2013</b> , 48, 1051-60	6.9	29
20	Evaluation of the Liver Fibrosis Index calculated by using real-time tissue elastography for the non-invasive assessment of liver fibrosis in chronic liver diseases. <i>Hepatology Research</i> , <b>2013</b> , 43, 735-42	5.1	18
19	Unfolded protein response pathways regulate Hepatitis C virus replication via modulation of autophagy. <i>Biochemical and Biophysical Research Communications</i> , <b>2013</b> , 432, 326-32	3.4	39
18	Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 21833-57	6.3	63
17	Hepatic triglyceride lipase plays an essential role in changing the lipid metabolism in genotype 1b hepatitis C virus replicon cells and hepatitis C patients. <i>Hepatology Research</i> , <b>2013</b> , 43, 1190-8	5.1	9
16	Transient elastography for monitoring the fibrosis of non-alcoholic fatty liver disease for 4 years. <i>Hepatology Research</i> , <b>2013</b> , 43, 979-83	5.1	21
15	Emerging drugs for non-alcoholic steatohepatitis. <i>Expert Opinion on Emerging Drugs</i> , <b>2013</b> , 18, 279-90	3.7	12
14	Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitis. <i>PLoS ONE</i> , <b>2013</b> , 8, e65211	3.7	34
13	Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , <b>2012</b> , 12, 16	3	160
12	Acoustic radiation force-based shear stiffness and non-invasive panels of tests in Japanese patients with nonalcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 740-1	13.4	1
11	Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. <i>Cell Metabolism</i> , <b>2012</b> , 16, 44-54	24.6	232
10	Plasma free choline is a novel non-invasive biomarker for early-stage non-alcoholic steatohepatitis: A multi-center validation study. <i>Hepatology Research</i> , <b>2012</b> , 42, 757-66	5.1	23
9	Peroxisome Proliferator-Activated Receptor Gamma Exacerbates Concanavalin A-Induced Liver Injury via Suppressing the Translocation of NF- $\kappa$ B into the Nucleus. <i>PPAR Research</i> , <b>2012</b> , 2012, 940384	4.3	11
8	Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 1933-9	5.6	11

7	Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin. <i>Hepato-Gastroenterology</i> , <b>2012</b> , 59, 1522-5		7
6	Liver abscess caused by periodontal bacterial infection with <i>Fusobacterium necrophorum</i> . <i>Hepatology Research</i> , <b>2011</b> , 41, 194-6	5.1	34
5	Time-course of changes of visceral fat area, liver volume and liver fat area during intragastric balloon therapy in Japanese super-obese patients. <i>Internal Medicine</i> , <b>2011</b> , 50, 2449-55	1.1	12
4	Novel findings for the development of drug therapy for various liver diseases: Liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis. <i>Journal of Pharmacological Sciences</i> , <b>2011</b> , 115, 270-3	3.7	7
3	Induction of microsomal triglyceride transfer protein expression is a candidate mechanism by which ezetimibe therapy might exert beneficial effects in patients with nonalcoholic steatohepatitis. <i>Journal of Gastroenterology</i> , <b>2011</b> , 46, 415-6; author reply 417	6.9	7
2	Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , <b>2011</b> , 46, 1300-6	6.9	77
1	Outcomes and factors influencing survival in cirrhotic cases with spontaneous rupture of hepatocellular carcinoma: a multicenter study. <i>BMC Gastroenterology</i> , <b>2009</b> , 9, 29	3	56